© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Eltrombopag Olamine did not arrive out of thin air—its origins trace back through decades of urgent hematological research. The medical community had grappled with severe thrombocytopenia, a condition that leaves patients vulnerable to bleeding risks. Blood disorders were handled by transfusions or steroids for ages, but those only put a patch on the problem. Back in the early 2000s, scientists began zeroing in on thrombopoietin (TPO), the hormone in charge of regulating platelet production. Pharmaceutical efforts merged biochemistry and clinical demand, eventually producing a new class of TPO receptor agonists. Amid setbacks and trial misfires, Eltrombopag rose through rigorous lab work and iterative clinical trials, relying on structural tweaks to shorten side effect profiles and boost absorption in humans, not just animals. Personal experience showed me the leap from concept to commercial therapy took cooperation between chemists and clinicians—it was a relay, not an individual sprint.
Across pharmacies and hospitals, Eltrombopag Olamine fills a gap left by older treatments. Its main medical purpose treats chronic immune thrombocytopenia, and it has expanded to help certain hepatitis C patients and folks with severe aplastic anemia. Unlike the rock-bottom options from my younger days in patient care, Eltrombopag gave folks another shot at reducing bleeding risk without tethering them to a hospital bed. The molecule, by mouth, fits neatly into daily routines, not unlike a morning vitamin, which makes adherence less of a chore. Patients typically take it in tablet form, available in various strengths for titration according to clinical response. Both the brand and generic forms carry clear labeling for strength, usage, and lot identification, qualifying as strong examples of transparent pharmaceutical packaging.
On the bench, Eltrombopag Olamine appears as a yellowish powder, a form that blends stability with ease of processing. It dissolves better in water than in organic solvents, a property that dictated much about tablet design when I followed its development. Structurally, it’s an olamine salt form of Eltrombopag, boosting shelf life and oral availability. The compound features a naphthalene core married to a pyridyl group, providing enough backbone rigidity to survive the harsh gastrointestinal environment. These physical properties made it easier for drug manufacturers to design consistent, stable dosage forms and sharply reduced pill-to-pill variability compared to older medications in this space.
Each production batch undergoes tight specification checks—purity usually exceeds 98 percent. Moisture content, heavy metal residue, and related compound profiles are measured with meticulous high-performance liquid chromatography and IR spectroscopy. Experienced regulatory teams ensure that every bottle bears a unique identifier, dosage strength, expiry date, and warnings about proper storage. I have seen firsthand how conscientious labeling reduces mistakes on the pharmacy floor, shielding patients from accidental overdoses or confusion, especially among seniors. On the patient instruction leaflets, manufacturers spell out dietary restrictions, notably avoiding dairy or mineral-rich foods within several hours before or after ingestion, due to absorption interference.
Manufacturing Eltrombopag Olamine calls for several stages of synthesis, not unlike building a complex car engine. Synthesis starts with carefully protected aromatic intermediates, requiring specialized reagents for each coupling reaction. After building the main molecular skeleton, chemists introduce the olamine, which acts as a stabilizing counterion. Each purification step—crystallization, filtration, and drying—impacts safety and final product reliability more than one might guess from the outside. Teams regularly recalibrate process parameters to clamp down on unwanted side products, always under scrutiny from both in-house quality engineers and outside auditors. Facilities handling this process keep strict environmental containment, minimizing worker exposure and environmental contamination.
Eltrombopag’s chemical structure opens up a few avenues for further tweaking. Chemists have tested analogues, swapping side chains or modifying the naphthalene ring to shorten half-lives or reduce off-target effects. The core carboxyl group permits salt formations for different formulations, although olamine proved the best for consistency and solubility when I observed hands-on experiments. After thorough preclinical screening, most modifications hit a wall of diminished bioactivity—underscoring that the current recipe already threads a fine needle, balancing potency with patient tolerance. Ongoing research explores how minor changes might lower long-term risks of liver toxicity, expanding the drug’s safe use window.
Outside the lab, Eltrombopag Olamine carries a handful of alternate names. You’ll hear it as Promacta in the United States and Revolade in Europe or Japan. Chemists and clinicians alike stick to “Eltrombopag” for brevity. Publications and batch sheets reference synonym codes like SB-497115-GR, a nod to the original development pipeline. For procurement and regulatory handling, the salt form—olamine—remains a critical detail, flagged across safety datasheets and supply manifests, warding off mix-ups with lesser-used versions.
Pharmaceutical-grade Eltrombopag Olamine production leans on hard-won SOPs enforced by agencies like the FDA and EMA. Exposure controls inside factories prevent inhalation or skin contact during granulation or tableting—workers wear dedicated suits and N95s, even though the powder isn’t respiratory toxic at brief exposures. Shipping and storage protocols require dry, light-protected conditions at room temperature to prevent degradation. Clinical settings stress liver function monitoring due to known hepatotoxicity risks; I recall case conferences where frequent bloodwork revealed subtle signs before symptoms ever surfaced. Strict adherence to risk evaluation and mitigation strategies (REMS) surrounds prescribing and dispensing, particularly in child and elderly populations.
Usage spans more than platelet counts. Eltrombopag helped change the management of refractory immune thrombocytopenia, shifting some patients off chronic steroids, which meant less brittle bones and fewer adrenal complications down the road. In hepatitis C, it recovered platelets enough for folks to stick with essential antiviral regimens, closing a treatment gap I saw frustrate liver specialists for years. Its approval for severe aplastic anemia opened doors for patients running out of bone marrow transplant options. While oncology teams sometimes tap it for chemo-induced low counts, guidelines continue to adapt as more data emerges from ongoing global use.
Research continues at full speed, with biotechs and academic centers both racing to unlock further uses for Eltrombopag Olamine. Combination studies with other hematopoietic agents show hints of synergy. Newer technology explores targeted delivery nanocarriers to boost concentrations in bone marrow while minimizing liver exposure. Laboratories experiment with Eltrombopag-like molecules for use in stem cell transplantation conditioning regimens. Personalized medicine tailors dosing through genetic studies mapping drug metabolism pathways in diverse populations. Each new clinical trial, from Canada to China, expands the understanding of where its strengths and shortcomings truly lie, leveraging electronic medical record registries to speed up post-market surveillance for rare adverse events.
Toxicology assessments drove much of the product’s evolution before it reached pharmacy shelves. Liver toxicity stands at the top of watch lists, with periodic increases in aminotransferase levels documented in a minority of patients. Past studies in rodents flagged cartilage thickening and cataract formation, but human data downplayed these effects, surfacing mostly in high-dose or long-term regimens. The risk of thrombotic events rises in certain high-risk groups, prompting careful patient selection. Toxicologists across industry and academia monitor water and soil near production plants for drug residue—chasing down environmental ramifications to prevent downstream contamination. Field feedback from treating physicians and pharmacovigilance networks feeds directly into safety labeling updates year after year.
The real question hovers on where therapies like Eltrombopag Olamine jump next. Researchers chase expansion into chemotherapy support, congenital platelet disorders, and rare genetic cytopenias. Digital health monitoring promises more accurate home-based dosing, reducing clinic time for fragile patients. Formulation scientists eye liquid or even injectable forms, boosting access in populations who struggle with tablets. Environmental sustainability demands greener synthesis methods, lighter packaging, and recycling of unused product stock. Advances in precision genomics hold promise for pinpointing who will benefit most—and who faces greatest risk—from ongoing use. As debates continue over cost and insurance coverage, policymakers, patient advocates, and hospital administrators all keep watch for what this therapy and its descendants could deliver next.
Life sometimes throws rare challenges. Low blood platelets—a condition called thrombocytopenia—can leave people bruising easily or bleeding longer from small cuts. For adults facing chronic immune thrombocytopenia (ITP), simple activities carry extra risk. That’s where Eltrombopag Olamine steps in. This medicine supports the body in making more platelets by stimulating the bone marrow. With more platelets, people with ITP can get back to daily life with fewer worries about unexpected bleeding.
Difficulties with platelets pop up in other places too. Cancer treatments, like chemotherapy, often hit blood count levels hard. Eltrombopag Olamine has also become a regular part of care for people dealing with severe aplastic anemia when other treatments don’t work. Over the years, doctors have come to trust the way it boosts platelet counts, especially in folks whose bodies haven’t responded to steroids or immunoglobulin.
This isn’t a treatment cooked up yesterday. The FDA reviewed studies with hundreds of patients before giving its nod in 2008. Research pointed to real benefits for many who stuck with the daily pills. People on Eltrombopag Olamine saw fewer bleeding episodes. Doctors tracked numbers and noticed platelet counts going up, often enough to cut back or stop other, riskier drugs. For some, the change felt like a second chance at normal life.
Every pill brings questions about possible downsides. Eltrombopag Olamine can bump up liver enzyme levels; for some, that means regular blood tests are part of the routine now. Food choices matter, too, since certain minerals or dairy can get in the way of how well the medicine works. Educating patients about timing each dose with meals helps the body get the most from treatment. As with many drugs, there’s always a balance to strike between benefits and risks.
Managing ITP, aplastic anemia, or the blood hits from hepatitis C used to leave people feeling stuck. Taking steroids long-term brings its own set of issues. Eltrombopag Olamine lets patients step away from medicines that cause weight gain, mood swings, or weak bones. As a result, people spend less time in emergency rooms or transfusion clinics. On a personal note, I’ve seen family members benefit from targeted treatments like this—getting them back to their favorite hobbies or travel plans.
Access to newer drugs often gets tangled up with insurance and pharmacy availability. The price remains a hurdle for some families. Policymakers and manufacturers need to keep talking, especially for rare diseases where patients can’t afford to go without options. Supporting patient assistance programs and expanding coverage helps bring these life-changing medicines into reach.
Medicines like Eltrombopag Olamine show how far research has come in just a few decades. People facing rare blood disorders still juggle doctor visits, ongoing tests, and the uncertainty of how their body will respond next month. Even so, knowing there’s a treatment built on evidence and years of use offers hope and a practical step forward. Better treatments and fair access to them don’t erase every problem, but they absolutely improve lives—one day, one dose, at a time.
Doctors often prescribe Eltrombopag Olamine to help boost low platelet counts caused by certain conditions, like chronic immune thrombocytopenia (ITP) or aplastic anemia. The way this medicine works ties directly to how it’s taken. I’ve seen people run into avoidable problems because they didn’t pay close attention to their doctor’s instructions or the information that comes with the pills.
Some patients believe pills can be swallowed at any time, with whatever meal comes next. But Eltrombopag interacts with foods and supplements that contain calcium, iron, or aluminum. Dairy, antacids, or even multivitamins can cut down the amount your body absorbs, which could stop the drug from working as expected. I once spoke with someone who saw their platelet count stubbornly low, only to realize their breakfast yogurt and Eltrombopag pill kept showing up together. Simple changes can make or break results.
People need to keep at least two hours between Eltrombopag and any food high in minerals. Even oatmeal with milk or a bowl of fortified cereal can make a difference. Taking the tablet on an empty stomach or far apart from meals gets better results. Healthcare teams tend to stress this. They’re not just being picky: consistent levels in the blood support a steadier platelet count, which keeps treatment more predictable. If someone finds themselves losing track, a reminder on the fridge or a phone alarm can help build the habit.
Doctors may change doses based on lab results. Missing appointments or not getting regular blood work can cause setbacks. Trust forms the core of therapy—patients counting on their care teams, and vice versa. If side effects show up, such as headaches, nausea, or changes in eyesight, doctors want to know right away. The faster people report these problems, the sooner a medication plan can be tailored.
Grapefruit and some herbal supplements, including St. John’s Wort, affect how the liver handles medicine. Avoiding them makes sense. Alcohol brings added risk—damaging the liver further and potentially complicating recovery. I know some who felt frustrated by all these rules, especially after lengthy battles with illness. Yet, keeping track grows easier with practice, and the confidence from more stable lab reports is a huge reward.
Family support changes everything. When caregivers or loved ones help keep an eye on schedules or offer encouragement, people stick to their routine. Pharmacies often have weekly pillboxes that sort medication by days and times. Hospital pharmacists explain interactions clearly and can suggest practical ways to avoid mistakes—like evening medication times for people who prefer skipping breakfast or whose routines stay unpredictable. Open conversations with the medical team often reveal tricks to simplify the process.
Paying attention to instructions for Eltrombopag Olamine makes a dramatic impact. Proper use helps people get the platelet numbers they need without unexpected drops or medical scares. This experience carries a bigger picture for all long-term therapies: small details, from food choices to timing, make the medicine work so much harder. Simple planning and support turn complicated regimens into something manageable for the whole family.
Eltrombopag Olamine gets used for some rare blood disorders, like chronic immune thrombocytopenia. The idea behind this drug is to boost platelet counts in the body. For some, the pill offers better day-to-day life, lowering the risk of spontaneous bruising or bleeding. That kind of progress matters, but real people taking this drug often want a heads-up on the less pleasant changes it might bring to their bodies.
After taking Eltrombopag Olamine, patients notice headaches, nausea, and fatigue show up often. I’ve talked to people who say they feel more tired than before – not the regular “bad night’s sleep” tired, but a bone-deep exhaustion. Some complain about stomach pain or diarrhea. According to clinical data, as many as 1 in 10 people taking this drug will face side effects like these. A dry mouth, mild rashes, and nagging muscle aches pop up too. These tend to fade as the body adjusts, but not always.
Liver issues grab the spotlight with Eltrombopag Olamine. Doctors check for liver enzymes in the blood to spot trouble early. The U.S. Food and Drug Administration issued warnings about this. If liver numbers start to rise, yellowing skin (jaundice), dark urine, or itching sets in, people have found themselves in emergency rooms more than once because they put off the signs. Anybody taking this drug ends up with more blood tests than usual and sometimes, stopped treatment because the risk of serious liver damage becomes real.
Platelets help blood clot, but raising them too high invites complications. Blood clots can block veins in the legs (deep vein thrombosis) or lungs (pulmonary embolism). Research in major journals reports these events remain rare, yet the danger isn’t just out there in the fine print – it shows up as swollen legs or sudden chest pain for some unlucky people. The problem: It’s tough to draw a line between the helpful rise in platelets and the tipping point where blood becomes too sticky.
Cataracts have cropped up in surprising numbers. For long-term users, regular eye checks matter. Bone marrow changes concern some doctors. Unusual changes in blood counts or worsened conditions can pop up in test results, sometimes without clear symptoms in daily life, leaving patients in a holding pattern between checkups.
The best move for anyone prescribed Eltrombopag Olamine comes down to close teamwork with the doctor. Regular bloodwork, honest conversations about new symptoms, and a review of all medicines and supplements could catch problems early. In my experience, people who stay informed about their lab tests and bring up even small changes—like mood swings, new bruises, or odd aches—tend to do better. Pharmacists and primary care providers also play a role, sometimes spotting interactions that slip past busy specialists.
Insurance plans and hospital programs sometimes help with monitoring expenses, since so many tests get ordered with this drug. With the stakes so high, no detail feels too small or petty to mention: Health hinges on details, shared experiences, and strong partnerships.
Eltrombopag olamine gives many people a second chance at keeping their platelet counts stable. Taken by mouth, it helps manage conditions like chronic immune thrombocytopenia and severe aplastic anemia. For anyone with a stack of pill bottles at home, a big question arrives quickly: Will eltrombopag mix safely with everything else in the box?
Most people dealing with low platelets don’t just have one health concern. They often juggle several prescriptions—from blood pressure pills to antacids and vitamins. I’ve watched family members struggle with complicated medication routines and know the stress that comes with tracking who can mix with what. A single oversight can create chaos in the body: bleeding risks with blood thinners, less power from the main drug, or even unexpected liver problems.
Research shows eltrombopag crosses paths with a few common medication groups. Antacids, supplements with calcium, aluminum, iron, magnesium, or zinc will cut its absorption. If you take eltrombopag too soon after a big glass of milk or a multivitamin, your body might miss out on most of the intended benefit. Doctors advise keeping a four-hour window between eltrombopag and these minerals. Skipping that buffer could leave someone with dangerously low platelets, even if they never miss a dose.
Some antibiotics, like ciprofloxacin or levofloxacin, and medications for cholesterol such as cholestyramine can change how much eltrombopag stays in the bloodstream. Hepatitis C treatments create their own headaches, since combining certain antivirals with eltrombopag can send liver enzymes climbing or trigger other side effects. The U.S. Food and Drug Administration points to liver lab tests as one more thing to track for anyone on this drug cocktail.
Not everyone reads fine print tucked into a pharmacy bag. One neighbor of mine ended up in the emergency room after stacking calcium pills with eltrombopag—he thought more “bone strength” could only help. Instead, it blocked the platelets from rising and forced his doctor to start from scratch. That type of avoidable scare pops up more than people realize. A recent study in Blood Advances found more than 30% of patients taking eltrombopag also picked up interfering minerals or other drugs at the same time.
Communication opens the safest path. Pharmacists see the full medication list and spot risks before problems surface. Bringing a complete, updated list to every doctor visit matters, even if the appointment feels routine. I’ve learned to ask direct questions: "Does anything I take block or boost this new drug?" Relying on memory or guesswork rarely pays off with something as serious as platelet disease.
Organizing medications with a clear schedule—color-coded charts, alarms, or pillboxes—helps keep track of timing between eltrombopag and other drugs or supplements. People who use online refill systems or medication tracking tools tend to have fewer mixups.
Managing chronic conditions feels overwhelming, especially with a growing medicine cabinet. By watching interactions with eltrombopag olamine, patients can keep treatments on track and avoid silent setbacks that often show up too late. Solid teamwork between patients, doctors, and pharmacists forms the backbone of safe care.
Eltrombopag Olamine helps people with low platelet counts, especially those dealing with chronic immune thrombocytopenia or problems from hepatitis C treatments. Relying on medication that tweaks how the body produces platelets always carries a balancing act. Some roll the dice with high expectations for their health, but misunderstandings or ignoring safety measures can bring trouble—some of it silent, some of it swift.
A big concern with eltrombopag comes down to the liver. As someone who’s taken prescription drugs for chronic issues, I’ve seen how easily folks can take their liver for granted. High doses of eltrombopag or skipping checkups can send liver enzymes surging. Labs may catch the warning signs, but without them, yellowing skin (jaundice), dark urine, or fatigue often get missed until they become severe. Regular blood tests are not just a safety net—they’re a vital habit, not just for the doctor but for the peace of mind of anyone on eltrombopag.
Increasing platelets improves bleeding risk, but too many can set off blood clots—in the leg, the lungs, sometimes in the brain. Having met patients post-hospitalization for deep vein thrombosis, I’ve learned how quickly clots can change the picture: pain, swelling, breathlessness are not theoretical risks but flashpoints for people using eltrombopag. Younger adults tend to think they’re invincible, but these risks care nothing for age when a medication raises platelet counts above the safe range. People on eltrombopag need vigilance for sudden pain or swelling more than they need optimism.
Eltrombopag does not mix kindly with everything. Too much calcium from dairy, antacids, iron, or supplements can choke off how the medicine gets absorbed. Picture someone taking their dose with a glass of milk each morning: the boost never reaches the bloodstream. Doctors and pharmacists have a duty—I’ve seen this in action—to hammer home that eltrombopag goes down best on an empty stomach. Patients who plan their meals—and keep a buffer between their medicine and anything rich in minerals—tend to see better results.
Some long-term side effects fly under the radar. People with hepatitis C who also take interferon and eltrombopag together have a higher risk for problems with their eyes, especially the retinas. Blurry vision or sudden visual changes never warrant waiting; they demand a call to the clinic. Catching these signs early matters far more than hoping they go away on their own.
Honest conversations about risks work best when someone feels heard rather than hurried. The single most productive step I’ve seen: setting up digital reminders for labs and drug schedules, and making friends with a pharmacist. Clear paperwork about what to avoid and what to look for puts power back into a person’s hands. That sense of control can mean the difference between responding quickly to a warning sign or ignoring it.
Taking eltrombopag isn’t a set-and-forget routine. Careful records, repeating labs, smart food choices, and a willingness to recognize trouble early all matter more than blind trust in the pill bottle. That’s how people stay on the safe side of progress.
| Names | |
| Preferred IUPAC name | 2-[(2S)-2-[(3'-[(2,6-dichloro-3-carbamoylphenyl)carbamoyl][1,1'-biphenyl]-2-yl)oxy]ethylamino]ethanol; 2-amino-2-methylpropan-1-ol |
| Other names |
Eltrombopag SB-497115-GR Revolade Promacta |
| Pronunciation | /ɛlˈtrɒmbəˌpæɡ oʊˈlæmɪn/ |
| Identifiers | |
| CAS Number | 496775-61-2 |
| Beilstein Reference | 17293016 |
| ChEBI | CHEBI:9506 |
| ChEMBL | CHEMBL1201731 |
| ChemSpider | 26740910 |
| DrugBank | DB06343 |
| ECHA InfoCard | 21e2ab44-ecdd-4b17-95e8-f8c3d2a05aa7 |
| EC Number | EC 1.14.16.1 |
| Gmelin Reference | **893877** |
| KEGG | D09675 |
| MeSH | D000077324 |
| PubChem CID | 24775612 |
| RTECS number | GZQ2U3V7Y6 |
| UNII | P32QKT967A |
| UN number | UN3275 |
| Properties | |
| Chemical formula | C46H63N5O11S |
| Molar mass | 564.65 g/mol |
| Appearance | Eltrombopag Olamine appears as a yellow to brownish-yellow tablet. |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | sparingly soluble |
| log P | 2.7 |
| Acidity (pKa) | 3.4 |
| Basicity (pKb) | 4.2 |
| Magnetic susceptibility (χ) | -94.2×10^-6 cm³/mol |
| Refractive index (nD) | 1.625 |
| Dipole moment | 3.9 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 610.6 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | B02BX05 |
| Hazards | |
| Main hazards | Suspected of causing cancer. |
| GHS labelling | GHS07, GHS08, Warning, H302, H315, H319, H361 |
| Pictograms | Tablet; Oral use |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. H373: May cause damage to organs through prolonged or repeated exposure. |
| Precautionary statements | Keep out of reach of children. Read the package leaflet before use. If you need medical advice, have the product container or label at hand. |
| NFPA 704 (fire diamond) | 1-1-0 |
| Lethal dose or concentration | LD50 (rat, oral): > 2000 mg/kg |
| LD50 (median dose) | > 2,000 mg/kg (rat, oral) |
| NIOSH | |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 50 mg once daily |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Eltrombopag Avatrombopag Lusutrombopag Romiplostim |
